Jefferies analyst Michael Yee upgraded Aligos Therapeutics (ALGS) to Buy from Hold with a price target of $3, up from $2.50. While 2022 was a challenging year, Aligos continues to work through its various pipeline assets, Yee tells investors in a research note. Most importantly, the stock is at a $40M market capitalization and a "promising" nonalcoholic steatohepatitis pill, says the analyst. He believes the asset was recently derisked by "very positive" Madrigal Pharmaceuticals (MDGL) Phase III fibrosis data.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALGS:
- Aligos Therapeutics upgraded to Buy from Hold at Jefferies
- Aligos on track to complete Phase 2-enabling activities in 2023 for ALG-055009
- Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
- Aligos Therapeutics initiates dosing in ALG-125755 trial
- Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
